

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: Official Statement of Patents and Trademarks Washington, D.C. 20231 www.unsptp.gov

			• •	
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/007,235	10/22/2001	Yat Sun Or	ENP-036	3609
759	90 02/07/2002			
Sandhya L. Kalkunte 500 Arsenal Street			EXAMINER	
Watertown, MA 02472			ANDERSON, REBECCA L	
			ART UNIT	PAPER NUMBER
		1	1626 DATE MAILED: 02/07/2002	2

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/007,235 OR ET AL.					
Office Action Summary	Examiner	Art Unit				
	Rebecca L Anderson	1626				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the o	correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status						
1) Responsive to communication(s) filed on						
	s action is non-final.					
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>1-24</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) ☐ Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) $\underline{1-24}$ are subject to restriction and/or e	election requirement.					
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Exa	aminer.					
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
1. Certified copies of the priority documents	have been received.					
2. Certified copies of the priority documents	have been received in Applicati	on No				
3. Copies of the certified copies of the priori application from the International Bur	eau (PCT Rule 17.2(a)).	-				
* See the attached detailed Office action for a list of the certified copies not received.						
<ul> <li>14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).</li> <li>a) ☐ The translation of the foreign language provisional application has been received.</li> </ul>						
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
) Notice of References Cited (PTO-892)  Notice of Draftsperson's Patent Drawing Review (PTO-948)  Information Disclosure Statement(s) (PTO-1449) Paper No(s)		r (PTO-413) Paper No(s) Patent Application (PTO-152)				

Application/Control Number: 10/007,235

Art Unit: 1626

## **DETAILED ACTION**

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-18 and 23 drawn to products of the formulas found in claim 1 on page 100, variously classified.
- II. Claims 19-22 drawn to various methods of use of the compounds of claim1, variously classified.
- III. Claim 24 drawn to a pharmaceutical composition comprising the compounds of claim 1 and additional antiviral agent(s), variously classified.

The above groups are identified as general areas. Accordingly, as groups they are independent or distinct as the inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used in a materially different processes as is clear from the instant specification (last full paragraph, page 30). The inventions I and III are distinct due to the additional antiviral agent which is materially different than that of invention I. Moreover, to not restrict in this application would result in a burden being imposed on the search and examination of this application. Because these inventions

Application/Control Number: 10/007,235

Art Unit: 1626

are distinct for the reasons given above, restriction for examination purposes as indicated is proper.

The above groups themselves are inclusive of patentably distinct subject matter.

Accordingly, along with the election of one of the above groups the following action is also taken.

Claims 1, 19, 24 are generic to a plurality of disclosed patentably distinct species comprising for example, the compounds of (1) example 001237 page 32 table 1, (2) example 00878 page 35 table 1, (3) example 001012 page 43 table 1, (4) example 000207 page 52 table 2, etc., (5) the method of treating HIV infection with the compound of 001237, etc., (6) the composition of the compound 001237 and saquinavir, etc.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 USC 103(a) of the other invention.

Upon election of a single disclosed species, a generic concept inclusive of the elected species will be identified by the Examiner for examination along with the elected species.

Application/Control Number: 10/007,235

Art Unit: 1626

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

An attempt was made to present this requirement telephonically but did not result in an election being made.

## Conclusion

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Rebecca L. Anderson whose telephone number is (703) 605-1157. Mrs. Anderson can normally be reached Monday through Friday 7:00AM to 3:30PM.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Mr. Joseph McKane, can be reached at (703) 308-4537.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone numbers are (703) 308-1235 and (703) 308-0196.

A facsimile center has been established. The hours of operation are Monday through Friday, 8:45AM to 4:45PM. The telecopier numbers for accessing the facsimile machine are (703) 308-4242, (703) 305-3592, and (703) 305-3014.

Patent Examiner

(

Art Unit 1626, Group 1620

Technology Center 1600

Robert Ramsuer

Primary Patent Examiner Art Unit 1626, Group 1620

Technology Center 1600